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Abstract We have studied the actions of the protein phospha-
tase inhibitor okadaic acid (OA) on the expression of bcl-2 in
HL60 human leukemia cells. OA induced downregulation of bcl-
2 mRNA and protein prior to the induction of apoptosis.
Downregulation of bcl-2 mRNA levels did not result from actions
of OA on the bcl-2 upstream negative response element. Nuclear
run-off analyses confirmed that OA did not affect bcl-2 gene
transcription. However, OA caused a rapid increase in the rate of
degradation of bcl-2 mRNA. Therefore, OA induces down-
regulation of bcl-2 expression via destabilization of its transcript.
The constitutive action of an OA-sensitive protein phosphatase
may therefore maintain HL60 cell survival by blocking bcl-2
mRNA degradation.
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1. Introduction
The sensitivity of cells to the induction of apoptosis is de-
termined by the relative levels of anti-apoptotic proteins, in-
cluding bcl-2 and bcl-XL and pro-apoptotic gene products
including bax [1]. Recent studies have shown that these pro-
teins regulate the release of cytochrome c from mitochondria
[2^4] and the consequent activation of caspases, the cysteine
proteases which initiate cell commitment to apoptosis [5].
High bcl-2 expression by malignant cells is an obstacle to
the treatment of some cancer patients. For example, high bcl-
2 expression by the malignant cells of acute myeloid leukemia
patients is associated with a poor response to chemotherapy
[6]. Therefore, the mechanisms which regulate bcl-2 expression
are important determinants of the sensitivity of some tumor
cells to cytotoxic regimes. Transcription of the bcl-2 gene is
initiated at two distinct promoter sites, P1 and P2. A 1.3 kb
negative regulatory element (NRE), located between P1 and
P2, potently downregulates transcription from P1 and from
heterologous promoters [7]. The biochemical mechanisms
which regulate P1, P2 and the NRE are poorly understood.
Okadaic acid (OA) inhibits protein phosphatase 2A (PP2A)
at low nanomolar concentrations and protein phosphatases 1
and 2B (PP1 and 2B) at higher levels [8]. OA induces apop-
tosis in a variety of tumor cell lines [9^12]. Here we show that
induction of apoptosis following OA treatment of HL60 cells
was preceded by the downregulation of bcl-2 mRNA and
protein levels via destabilization of bcl-2 transcripts.
2. Materials and methods
2.1. Cell culture and quantitation of apoptosis
HL60 acute promyelocytic leukemia cells were maintained as de-
scribed [13]. Apoptosis was quantitated by the terminal transferase-
mediated £uoresceinated dUTP nick end-labelling (TUNEL) method
using the Apoptosis Detection System (Promega, Southampton, UK).
In some experiments, apoptosis was quanti¢ed by FACScan analysis
of cells containing a sub-diploid DNA content [14].
2.2. Competitive reverse transcriptase polymerase chain reaction
(RT PCR) procedures
Relative levels of actin and bcl-2 transcripts were quantitated by
competitive reverse transcriptase polymerase chain reaction (RT PCR)
[15] using primers and internal standard mimic templates as detailed
elsewhere [16]. PCR products were quantitated by Southern blot hy-
bridization [16] and densitometric scanning.
2.3. Western blotting
Protein extraction and Western blot analysis were as described [13].
2.4. Construction and electroporation of luciferase reporter plasmids
The control plasmid pCMV-GL2 (Fig. 3) was derived by blunt-end
cloning of the NheI-NsiI CMV promoter fragment of pBKCMV
(Stratagene, UK) into the SmaI site located upstream of the luciferase
gene of the pGL2 reporter plasmid (Promega, UK). pCMV-GL2-bcl2
(Fig. 3) was constructed by sub-cloning a bcl-2 upstream genomic
sequence into pGL2. Details of cloning procedures are available on
request. Ten million HL60 cells were suspended in 0.4 ml OptiMEM
(Life Technologies, Paisley, UK) and transfected with 10 Wg plasmid
at 960 WF and 300 V using a Gene Pulser (Bio-Rad, UK). Expression
from reporter constructs was quantitated using the Luciferase Assay
System (Promega, UK).
2.5. Run-o¡ transcription assays
Run-o¡ assays were carried out as described [17]. Control experi-
ments in which K-amanitin (Sigma, Poole, UK) was included in the
run-o¡ reactions abolished hybridization to both bcl-2 and actin tar-
gets (not shown).
2.6. Estimation of mRNA stability
HL60 cells were treated with 1 Wg ml31 actinomycin D in the
presence or absence of 20 nM OA. RNA was isolated from 2U106
cell aliquots at 1 h intervals [18]. As a control for recovery, 109 copies
of the synthetic mouse TEL RNA transcript [19] were added to each
0.5 ml of RNA extraction solution. Relative bcl-2 and actin transcript
levels were determined by competitive RT PCR [16].
3. Results
3.1. OA-induced apoptosis of HL60 cells is preceded by
downregulation of bcl-2 protein and mRNA
Following the addition of 20 nM OA to HL60 cultures, a
small increase in TUNEL-positive apoptotic cells was evident
at 24 h. However, substantial induction of apoptosis was not
detected until 48 h. Concentrations of OA above 10 nM in-
duced apoptosis of HL60 cells in a dose-dependent manner
(Fig. 1B). Expression of the structural protein actin was es-
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sentially unchanged up to 48 h after addition of 20 nM OA.
Bcl-XL expression was also una¡ected. By contrast, a marked
downregulation of bcl-2 protein occurred between 24 and 39 h
(Fig. 2A).
Bcl-2 cDNA probes cross-hybridize to ribosomal RNA on
Northern blots [20]. We therefore used a competitive RT PCR
procedure [15,16] for semi-quantitative analysis of bcl-2 and
actin transcripts. Bcl-2 mRNA levels were markedly decreased
between 5 and 24 h following OA addition, whereas actin
transcripts were substantially more stable (Fig. 2B).
3.2. E¡ects of OA on the activity of the bcl-2 NRE
The plasmid pCMV-GL2, which contains the CMV pro-
moter inserted immediately 5P of the luciferase gene, gave a
strong signal on transfection into HL60 cells (Fig. 3A). Luci-
ferase expression by this plasmid was una¡ected by OA (Fig.
3A). Insertion of the bcl-2 NRE between the CMV promoter
and the luciferase reporter in plasmid pCMV-GL2-bcl2 re-
sulted in a strong inhibition of luciferase expression compared
to pCMV-GL2 (compare control transfections in Fig. 3A and
B). Therefore, the bcl-2 NRE is functional in HL60 cells.
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Fig. 1. Induction of apoptosis in OA-treated HL60 cells. A: The
percentage of apoptotic cells was determined by TUNEL assay. B:
HL60 cells were incubated for 48 h with increasing concentrations
of OA. Apoptotic cells were quantitated by FACScan analysis.
Fig. 2. A: Western blot analysis for actin, bcl-XL and bcl-2. Hours
of incubation with 20 nM OA are indicated under the lanes. B:
Competitive RT PCR determination of actin and bcl-2 mRNA in
OA-treated HL60 cells. Hours of incubation with OA are indicated
above the lanes. Lane B: Reverse transcriptase reagent blank (RNA
omitted).
Fig. 3. Actions of OA on luciferase reporter activity in HL60 cells. HL60 cells were electroporated with 10 Wg pCMV-GL2 (A) or pCMV-GLC
(B). Structures of the plasmids are shown. Bcl-2 upstream sequences are in cross-hatch. Each pool of transfected cells was immediately divided
into four aliquots. Two aliquots were incubated in the presence of 20 nM OA for 24 h prior to extraction and assay for luciferase activity
while the remaining two aliquots were left untreated. Luciferase activities were normalized with respect to protein content to allow for small
variations in extraction e⁄ciency. Note di¡erent scales in A and B.
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However, OA did not further reduce luciferase expression by
pCMV-GL2-bcl2 (Fig. 3B), indicating that the downregula-
tion of bcl-2 transcripts induced by this agent (Fig. 2B) was
not mediated via an action on the NRE. Similar results were
obtained in an independent experiment.
3.3. Run-o¡ analysis of bcl-2 transcripts
Following 24 h OA treatment, the level of actin-speci¢c
run-o¡ transcription had declined, whereas bcl-2 transcription
was only marginally a¡ected (Fig. 4). Scanning densitometry
of two separate run-o¡ hybridizations showed an OA-induced
decline in actin transcription of 80% and 69%. Bcl-2 run-o¡
transcription was augmented by 12% in OA-treated cells in
the ¢rst experiment and decreased by 16% in the second.
Therefore, the marked decline in steady-state bcl-2 transcripts
observed 20 h following OA addition was not attributable to
an e¡ect of the inhibitor on bcl-2 transcription. The mainte-
nance of actin mRNA levels in OA-treated cells (Fig. 3B)
despite the decrease in transcription rate (Fig. 4) may be at-
tributable to the relative stability of these transcripts [21].
3.4. Stability of bcl-2 and actin transcripts in OA-treated
HL60 cells
Finally, we estimated the stability of bcl-2 transcripts in
HL60 cells following blockade of transcription by actinomy-
cin D. Incubation was terminated at 3 h because actinomycin
D itself induced caspase activation at 5 h and morphologically
observable apoptosis at 6 h (not shown). Comparable RNA
recovery and reverse transcription of all samples was moni-
tored by RT PCR analysis of a synthetic TEL RNA transcript
which was added at the time of cell lysis (Fig. 5A). E⁄ciency
of individual RT reactions as well as loading and Southern
blot transfer of products were controlled by the use of internal
PCR controls [15,16].
In the absence of added OA, bcl-2 and actin transcripts
were essentially stable following actinomycin D addition
(Figs. 5B and 6). By contrast, bcl-2 mRNA was rapidly de-
graded in HL60 cells incubated in the presence of both actino-
mycin D and OA (Figs. 5B and 6). The stability of actin
transcripts was not decreased by OA addition, suggesting
that the e¡ect of OA on bcl-2 mRNA stability was not the
result of a general e¡ect on mRNA stability. The OA-induced
decrease in stability of bcl-2 transcripts was seen in two addi-
tional experiments.
4. Discussion
Here we have shown that OA-induced apoptosis of HL60
cells was preceded by downregulation of bcl-2 protein. There-
fore, the decrease in bcl-2 levels may contribute to OA-in-
duced cell killing. By contrast, levels of bcl-XL protein were
not downregulated.
Bcl-2 mRNA levels declined dramatically by 20 h after ad-
dition of OA to HL60 cells, suggesting that OA-induced bcl-2
downregulation was the result of decreased transcript levels.
Reporter transfection studies showed that bcl-2 mRNA down-
regulation was not modulated via the upstream NRE of the
bcl-2 gene. Run-o¡ analyses con¢rmed that transcription of
the bcl-2 gene was una¡ected by the inhibitor. However, OA
treatment resulted in the rapid destabilization of bcl-2
mRNA. It is unlikely that this destabilization was the conse-
quence of apoptosis, since the decrease in bcl-2 mRNA half-
life was observed within 3 h of OA addition, whereas apop-
totic changes were not evident until 24 h.
In contrast to the relatively slow induction of apoptosis by
20 nM OA, micromolar levels of this inhibitor induced apop-
tosis within 2 h [10]. Apoptosis induction was associated with
enhanced serine phosphorylation of bcl-2, which inhibits its
ability to neutralize the cytotoxic actions of bax [22]. This
action of OA may be mediated by inhibition of protein phos-
phatase 2B [10]. The slow induction of apoptosis by 20 nM
OA reported here may be attributable to a di¡erent mecha-
nism involving bcl-2 downregulation resulting from the inhib-
ition of PP2A or PP1.
In conclusion, the data here suggest that the constitutive
activity of an OA-sensitive protein phosphatase contributes
to the survival of HL60 cells by maintaining stability of bcl-
2 mRNA. Earlier observations that ectopic expression of bcl-2
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Fig. 4. Run-o¡ analysis of actin and bcl-2 gene transcription. Equal
counts min31 of radiolabelled run-o¡ transcripts from control (3)
or 24 h OA-treated (+) HL60 cells were hybridized to 5 Wg dot-blot-
ted actin (A) or bcl-2 (B) cDNA targets. Run-o¡ transcripts did not
hybridize to empty vector (not shown).
Fig. 5. Estimation of degradation rate of bcl-2 transcripts. HL60 cells were treated with 1 Wg ml31 of actinomycin D in the presence or absence
of 20 nM OA. RNA was extracted at intervals using a lysis solution containing a synthetic TEL gene transcript. A: Each sample was analyzed
by RT PCR to assess recovery of the TEL transcript. B: RT PCR analysis for actin and bcl-2 mRNA. Open diamond, mimic band; closed tri-
angle, bcl-2 band; closed diamond, actin band. The time (hours) after actinomycin D addition is shown above each lane.
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inhibited OA-induced apoptosis in K562 cells [12] is compat-
ible with this hypothesis.
Aberrant regulation of PP2A may play a role in leukemo-
genesis. The SET gene, which is translocated to the Nup214
gene in some cases of myeloid leukemia [23] encodes an in-
hibitor of PP2A [24]. It is therefore possible that impaired
regulation of PP2A may contribute to leukemogenesis in cells
expressing the chimeric SET/Nup214 oncoprotein. Therapeu-
tic modulation of the activity of PP2A-dependent pathways
may therefore provide a means of enhancing the sensitivity of
some tumor cells to the induction of apoptosis by cytotoxic
drugs.
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Fig. 6. Rate of decay of actin and bcl-2 transcripts in HL60 cells treated with actinomycin D. The densitometric intensities of the actin and
bcl-2 bands shown in Fig. 5B were normalized with respect to the appropriate mimic band and plotted against the time (hours) after actinomy-
cin addition. The band/mimic ratio at time zero was set at unity.
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